429results about How to "Small toxicity" patented technology

The invention relates to a nano antibody targeting cadherin 17 and application thereof, and relates to the technical field of immunology and molecular biology, the amino acid sequence of a complementary determining region of the nano antibody targeting cadherin 17 comprises CDR1 shown as any one of SEQ ID NO: 21-32, CDR2 shown as any one of SEQ ID NO: 34-45, and CDR3 shown as any one of SEQ ID NO: 47-58. According to the invention, an alpaca immune phage display library is constructed, a series of nano antibody molecules targeting cadherin 17 (CDH17) are screened from the alpaca immune phage display library, and functions and applications of the nano antibody are verified at various levels of CDH17 antigen protein, CDH17 target cells, CDH17 CAR-T cells and the like.

The invention discloses an RNA (Ribonucleic Acid) in-vitro cyclization and rolling circle translation method based on an I-type intron and an application of the RNA in-vitro cyclization and rolling circle translation method. According to the invention, a ribonucleic acid construct is obtained by splitting a specific non-complementary region of the I-type intron, and the preparation of'scarless' (traceless) circular RNA is realized through a ribozyme self-splicing principle and can be popularized to other I-type intron. By optimizing a splitting structure, high-efficiency cyclization can be realized without additionally adding GTP for catalysis under the condition of no homologous arm. Meanwhile, the original part of the ribonucleic acid construct is optimized, so that the cyclization efficiency is further improved. Particularly, a rolling circle translation (RCT) technical platform based on the CITE sequence is established, and the expression quantity of the protein or the polypeptide is greatly improved. Through verification, the cyclization and rolling circle translation method provided by the invention shows potential in vaccine and CAR treatment, and is expected to be used for clinical treatment of various diseases.

The invention relates to a humanized nano antibody targeting cadherin 17 and application of the humanized nano antibody, and relates to the technical field of immunology and molecular biology. The complementarity determining region of the humanized nano antibody comprises a CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, a CDR2 of which the amino acid sequence is shown as SEQ ID NO: 4 and a CDR3 of which the amino acid sequence is shown as SEQ ID NO: 6; a framework region of the humanized nano antibody comprises an FR1 of which the amino acid sequence is shown as any one of SEQ ID NO: 1 and SEQ ID NO: 8, an FR2 of which the amino acid sequence is shown as any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 11, an FR3 of which the amino acid sequence is shown as any one of SEQ ID NO: 5 and SEQ ID NO: 10, and an FR4 of which the amino acid sequence is shown as SEQ ID NO: 7. According to the humanized nano-antibody, the immunogenicity of the nano-antibody is reduced, the targeted binding activity and killing activity are improved, and the humanized nano-antibody can be used for developing immunodetection reagents, CAR-T / NK cell drugs and antibody drugs.

The invention provides a soak solution for a corneal contact lens, a preparation method of the soak solution and the corneal contact lens, and the soak solution is mainly prepared from the following raw materials in percentage by mass: 0.01%-0.15% of litamilast, 0.01%-0.15% of sodium dodecyl benzene sulfonate, 0.01%-0.15% of sodium dodecyl benzene sulfonate and the balance of water. 0.1%-2% of buffer salt; 0.2%-1.2% of sodium chloride; 0-0.5% of sodium thiosulfate; and 97%-99% of purified water. The soak solution for the corneal contact lens prepared by the invention can well interact with water molecules in the corneal contact lens, so that drug molecules in the soak solution are well replaced in the corneal contact lens, and the drug molecules are retained in a gel network of the corneal contact lens; the bioavailability of the medicine is improved while high medicine loading capacity is realized, and the corneal contact lens prepared from the soak solution has the effect of slowly releasing the medicine, directly acts on eyes and can reduce the toxic and side effects of the medicine.

The invention discloses a polypeptide derivative with a GCGR, GIPR and GLP-1R triple targeting agonistic effect as well as a preparation method and application of the polypeptide derivative, the polypeptide derivative is shown as a formula (I), (II) is a branched chain modification structure of a peptide chain, and the group definition is detailed in the specification. The polypeptide derivative compound and the pharmaceutically acceptable salt thereof provided by the invention can be used for treating metabolic related diseases such as diabetes mellitus, weight loss, MASH and the like, cardiovascular and cerebrovascular diseases and / or neurodegenerative diseases. Tyr-Aib-Gln-Gly-Thr-Ph-Thr-Ser-Asp-Tyr-Ser-Xaa12-Xaa13-Leu-As-Lys-Xaa17-Ala-Gln-Xaa24-Xaa25-Leu-Leu-Xaa28-Gly-Ala-Pro-Pro-Ser-NH2 (I) # imgabs0 #

The invention discloses an anti-adhesion membrane loaded with nintedanib and a preparation method of the anti-adhesion membrane loaded with the nintedanib. The anti-adhesion membrane loaded with the nintedanib is prepared from a drug-loading substrate material and the nintedanib through electrostatic spinning, the material of the drug-loading substrate is one or more of polylactic acid, poly (p-dioxanone), a polylactic acid-glycolic acid copolymer, polycaprolactone and polyethylene glycol; a solvent adopted in the electrostatic spinning is hexafluoroisopropanol, and the voltage adopted in the electrostatic spinning is 10-14 kV. The nintedanib-loaded anti-adhesion membrane has the advantages that the tensile strength and the elongation at break are obviously improved, the mechanical property is obviously improved, the fiber distribution is uniform, the obvious anti-adhesion effect is realized, the nintedanib-loaded anti-adhesion membrane is suitable for common laparotomy, and the application prospect is wide.

The invention provides a genetically engineered bacterial exosome vesicle and application thereof in preparation of a medicine for treating tumors, and comprises a genetically engineered bacterial exosome vesicle Neo-MICBOMVs, and the surface of the genetically engineered bacterial exosome vesicle Neo-MICBOMVs is loaded with a fusion protein composed of a tumor neoantigen protein and an MICB [alpha] 3 structural domain protein. The fusion protein can be used as a vaccine pharmaceutical composition for treating tumors, can be used as a targeting antigen presenting cell, can promote activation of an immune system, can increase immune infiltration in a tumor microenvironment, can inhibit immune escape of tumor cells, and can improve the effect of tumor immunotherapy.

The invention discloses a method for enhancing Candida albicans biofilm resistance of azole drugs by using a zinc ion chelating agent, through the combined action of the zinc ion chelating agent N, N, N ', N'-tetra (2-picolyl) ethylenediamine (TPEN) and fluconazole, the activity of the Candida albicans biofilm can be reduced, and the Candida albicans biofilm can be enhanced. The early-stage adhesion process, the medium-stage yeast-to-hypha conversion process and the late-stage maturation process formed by the candida albicans biological membrane are inhibited, the structure of the candida albicans biological membrane is destroyed, then the high drug resistance of the candida albicans biological membrane to fluconazole is reversed, and the pathogenicity of the fluconazole is reduced; the problems of high drug resistance and sustained infection caused by the formation of a candida albicans biofilm are hopefully solved, and a direction is provided for the treatment of clinical fungal infection and the research and development of drugs.

The invention belongs to the technical field of medicines, and discloses photosensitizer-entrapped tumor cell membrane bionic metal organic framework nanoparticles as well as preparation and application thereof. The photosensitizer-entrapped tumor cell membrane biomimetic metal organic framework nanoparticles are prepared by adopting a tumor cell membrane biomimetic camouflage technology and coating the surface of the metal organic framework nanoparticles with the photosensitizer through repeated membrane extrusion or ultrasonic treatment. The preparation process is simple, the cost is low, and a complex synthesis process is not needed. The bionic nanoparticle disclosed by the invention has the functions of homologous targeting and immune escape, and is beneficial to prolonging the in-vivo circulation time and realizing higher tumor tissue targeting. In addition, the bionic nanoparticles can kill tumor cells through a photodynamic effect, and have the advantages of good therapy and low toxic and side effects.

The invention discloses an osthole compound, a metal complex and a preparation method and application of the osthole compound, the osthole compound (OST-Alkyne) has remarkable anti-tumor biological activity, osthole (OST) and a cyclometalated iridium precursor are further connected through a copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction, higher anti-tumor activity is shown, and the osthole compound has a good application prospect. Mitochondria is targeted, and tumor is killed by reducing mitochondrial membrane potential and inducing cell autophagy and necrotic apoptosis; according to the invention, natural products are combined with metals, so that not only are good selectivity and anti-proliferation ability to brain glioma cells realized, but also toxic and side effects to normal cells are overcome, a new design idea is provided for novel metal drugs to treat brain glioma, and the application prospect is wide.

The invention belongs to the technical field of biological medicines, and particularly relates to sodium pyruvate sustained-release gel nanoparticles based on redox response as well as a preparation method and application of the sodium pyruvate sustained-release gel nanoparticles. The preparation method comprises the following steps: adding modified gellan gum containing sulfydryl and catechol groups, phenylboronic acid modified gellan gum and sodium pyruvate into water to obtain a mixed solution; under the protection of inert gas, divalent metal salt and potassium persulfate are added into the mixed solution, stirring is performed for 3-5 h, after the reaction is finished, centrifugation is performed, precipitates are collected, washed and dried, and the composite material is obtained. Experimental results show that the sodium pyruvate sustained-release gel nanoparticles prepared by the invention can realize controlled release of drugs, reduce toxic and side effects caused by burst release of the drugs, improve the curative effect of the drugs and improve the bioavailability.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum fermentation liquor and application thereof. The lactobacillus plantarum fermentation liquor provided by the invention is obtained by taking roses as a substrate and fermenting screened plant milk stalks under specific conditions. Experimental results show that the content of effective active ingredients such as total polyphenol, total polysaccharide and superoxide dismutase in rose fermentation liquor fermented by the lactobacillus plantarum is relatively high, and the fermentation effect of the rose fermentation liquor is far superior to that of commercially available common lactobacillus plantarum and other strains; besides, the rose fermentation liquor also shows obvious DPPH free radical and hydroxyl free radical scavenging ability, can effectively inhibit the activity of tyrosinase and improve the cell viability, has anti-aging and whitening effects, and can be widely applied to various foods and skin care products.

According to the nitrogen hydrochloride # imgabs0 # stine eye drops for treating allergic conjunctivitis and the preparation method of the nitrogen hydrochloride # imgabs0 # stine eye drops, the prepared eye drops can interact with the mucous layer on the surface of keratoconjunctiva by selecting specific solid lipid and a surfactant and controlling the dosage of the solid lipid and the surfactant; the retention capacity of the medicine in front of the cornea is prolonged, so that the medicine has good targeting property, the continuous release of the medicine is realized, the medication frequency can be reduced, the toxic and side effects of the medicine are reduced, the bioavailability is improved, the medication compliance of a patient is enhanced, and in the preparation and long-term storage processes, the medicine has better stability, and is suitable for popularization and application. Therefore, the problems of excessive drug due to multiple administration and poor stability of the active component nitrogen hydrochloride # imgabs1 # stine are solved.

The invention discloses a wound-targeted intelligent nano-drug as well as a preparation method and application thereof. The wound-targeted intelligent nano-drug comprises a platelet membrane and drug-loaded nano-particles, wherein the platelet membrane coats the drug-loaded nano-particles; the drug-loaded nanoparticles contain a tumor angiogenesis inhibitor; the surface of the platelet membrane is connected with an anti-PDL1 antibody. The wound-targeted intelligent nano-drug can significantly improve the curative effect of a tumor angiogenesis inhibitor (sorafenib) and anti-PDL1 combined use, improve the biological distribution of the drug, reduce the toxic and side effects caused by the combined use of the sorafenib and anti-PDL1, greatly reduce the postoperative recurrence rate of early liver cancer, has a strong postoperative recurrence inhibition capability, and has a good application prospect. The biological safety is relatively excellent.

The invention discloses application of lupane derivatives in preparation of medicines for preventing and / or treating drug-induced deafness, and belongs to the field of biological medicines. The lupane derivative is represented by Chiisanoside, and experiments prove that the lupane derivative can activate the expression of Dock1 and PIP5K1A, inhibit the expression of Gelsolin and inhibit hair cytoskeleton actin instability induced by ototoxic drugs, and the lupane derivative has the advantages that the lupane derivative can be used for inhibiting the ototoxic drug-induced hair cytoskeleton actin instability, and the lupane derivative can be used for inhibiting the ototoxic drug-induced hair cytoskeleton actin instability; in addition, by activating expression of TGFBR2, SLC7A11 and GPX4 at the same time, hair cell ferroptosis induced by ototoxic drugs can be inhibited; further, the effects of preventing, treating or relieving the drug-induced deafness are exerted. The lupane derivative disclosed by the invention can be further developed into a multi-target therapeutic drug for preventing, treating and relieving drug-induced deafness.

The invention discloses sprayable hydrogel for healing a bacterial infected wound and a preparation method of the sprayable hydrogel. The preparation method comprises the following steps: preparing a g-C3N4 nanosheet by taking melamine as a precursor, and then preparing AuNPs-C3N4 nano-enzyme on the g-C3N4 nanosheet through in-situ reduction of HAuCl4. 3H2O; preparing oxidized hyaluronic acid through a sodium periodate oxidation method; the preparation method comprises the following steps: incubating an AuNPs-C3N4 nano-enzyme solution and a glucose solution, adding a Mn < 2 + >-containing manganese salt solution and a bicarbonate solution, then mixing with an oxidized hyaluronic acid solution to obtain a dispersion liquid, spraying the dispersion liquid and a carboxymethyl chitosan solution in a cross-phase manner, and carrying out a Schiff base reaction to prepare the AuNPs-C3N4 / Glu / Mn < 2 + >-carboxymethyl chitosan-OHA hydrogel. The method is simple in preparation process, and the prepared hydrogel can have excellent in-vitro antibacterial efficiency, good biocompatibility and bacterial adsorbability, and can effectively remove bacteria at wound infection parts and promote wound healing.

The invention belongs to the technical field of medicines, and discloses a lonidamine-entrapped tumor cell membrane bionic metal organic framework nanoparticle as well as preparation and application thereof. The preparation method comprises the following steps: firstly, preparing lonidamine-entrapped metal organic framework nanoparticles by adopting a one-pot method, then coating tumor cell membranes on the surfaces of the nanoparticles through repeated membrane extrusion or ultrasonic treatment, and finally preparing the lonidamine-entrapped tumor cell membrane bionic nano-drug. The preparation process is simple, the cost is low, the stability is good, and the repeatability is high. The bionic nano-drug disclosed by the invention is helpful for solving the problems of poor solubility, low bioavailability and the like of an anti-cancer drug lonidamine. And meanwhile, the tumor cell membrane camouflage technology can promote the nano-drug to realize relatively high tumor tissue accumulation by utilizing the dual effects of EPR passive targeting effect and homologous active targeting, so that the anti-tumor effect is improved, and the toxic and side effects of lonidamine are reduced.

The invention belongs to the technical field of tumor vaccines, and discloses a personalized tumor vaccine based on hydrogel and a preparation method and application thereof, the preparation method comprises the following steps: adding a chemotherapeutic drug into a mixed solution of polyphenol and metal ions, uniformly mixing, adjusting the pH value of the solution, and reacting for 2-8 hours to obtain a metal polyphenol nano-carrier loaded with the chemotherapeutic drug; co-culturing the obtained metal polyphenol nano-carrier loaded with the chemotherapeutic drug and tumor cells for 12-48 hours, and inducing the tumor cells to generate immunogenic cell death, wherein the concentration of the metal polyphenol nano-carrier loaded with the chemotherapeutic drug is 1-20 [mu] g / mL; the tumor cell suspension in the ICD state and the STING agonist solution are mixed with the sodium alginate solution, and the personalized tumor vaccine is obtained. The ICD is induced in vitro by the chemotherapeutic drug, so that the toxic and side effects of systemic administration are reduced, the types of antigens are enriched, and a powerful guarantee is provided for the vaccine to activate a strong in-vivo anti-tumor immune response.

The invention discloses a self-assembled polypeptide nano-enzyme and application thereof, the self-assembled polypeptide nano-enzyme comprises a polypeptide scaffold, a polypeptide sequence with targeting and nano-enzyme affinity, a main body with amino acid having a characteristic sequence derived from natural enzyme and a functional motif containing hydrophobic peptide, the polypeptide nanoparticles are self-assembled by utilizing the hydrophobic interaction of amino acids; the nano enzyme is in coordination binding with the central coordination amino acid; and the targeting peptide is positioned at the N end of the polypeptide sequence and is displayed on the outer layer surface of the self-assembled polypeptide nanoparticle. According to the invention, the high-activity nano-enzyme is biomimetically designed by simulating a natural enzyme metal ion active site and a spatial structure of a catalytic microenvironment. The novel polypeptide nano-enzyme with targeting property and biosafety is constructed by taking polypeptide as a synthesis template. The self-assembled polypeptide nano-enzyme can be administrated through aerosol inhalation, targeted positioning of the nano-enzyme on a focus is guided, ROS of focus tissue is regulated and controlled, and occurrence and development of diseases are inhibited.

The invention discloses a preparation method of a homologous tumor cell and American ginseng composite exosome, and belongs to the field of functional medical materials and nanotechnologies, and the preparation method comprises the following steps: S1, separating a U87 cell exosome from a U87 cell by using a continuous ultracentrifugation method, and preparing U87-Exos for later use; s2, separating American ginseng exosomes from American ginseng rhizomes by using a continuous ultracentrifugation method, and preparing AG-Exos for later use; s3, the U87-Exos obtained in the step S1 and the AG-Exos obtained in the step S2 are subjected to extrusion compounding, and U87 / AG-Exos is prepared; s4, temozolomide and resveratrol are dissolved in a solvent and mixed with the U87 / AG-Exos obtained in the step S3, and then the mixed solution is subjected to ultrasonic treatment. According to the exosome preparation method, a medicine delivery system based on homologous tumor cell composite Exos is prepared, TMZ and RES are jointly delivered and used for treating GBM, the medicine delivery system is based on the concept of traditional Chinese medicine combination therapy, the limitation of traditional chemotherapy is overcome, and a promising strategy is provided for treating GBM.

The invention relates to the field of biological medicine, and discloses application of a biphenyl cyclooctene lignan compound and a chemotherapy sensitizing drug. The biphenyl cyclooctene lignan compound can be used for preparing a chemotherapy sensitizing drug, and the chemotherapy sensitizing drug is an ovarian cancer chemotherapy sensitizing drug, and can improve the sensitivity of cells to paclitaxel and inhibit the activity, proliferation and migration of the cells. The biphenyl cyclooctene lignan compound is combined with paclitaxel, so that the cell activity of the ovarian cancer paclitaxel drug-resistant cell A2780 / Taxol can be remarkably reduced, and the cell survival rate is only 31.13%. The combination of the biphenyl cyclooctene lignan compound and paclitaxel can also be used for preparing chemotherapy sensitizing drugs.

The invention discloses a preparation method of a pyridino-isoquinoline-2-ketone derivative, which comprises the following steps: under the protection of nitrogen, putting 1-aryl-3, 3-difluorocyclohexene, brominated N-(2-phenyl-2-oxo) ethyl isoquinolinium, alkali and a solvent into a reactor, reacting at 60 DEG C for a period of time, and then adding tert-butyl hydroperoxide to continue reacting; and after the reaction is finished, reducing pressure to remove the solvent, and carrying out column chromatography separation to obtain a pure product of the pyridino isoquinoline-2-ketone derivative. Initial raw materials are cheap, easy to obtain and wide in source, and products are complex and diversified in structure. The process flow is simple, and operation is simple and safe. Double bonds conjugated with two carbonyl groups in the target product can be further subjected to functionalization reaction, so that the target product can be conveniently subjected to diversified structural modification.

The invention discloses a click type covalent drug as well as a regioselective delivery system and application thereof. The click-type covalent drug delivery system comprises a click-type covalent drug and a tumor region selective delivery system, and the click-type covalent drug is composed of aza-cyclic alkyne (DBCO), a small molecule drug and a linker and has a structure as shown in a formula 1. Optionally, the small molecule drugs are membrane protein inhibitors, immunomodulators, chemotherapeutic drugs and the like. The click-type covalent drug and the azide-labeled target cell are subjected to a click reaction to form a covalent bond to be combined on a cell membrane, so that the local drug concentration is improved, the drug retention time is prolonged, and the selective inhibition on the target cell is enhanced; the regioselective delivery system is formed by co-assembling an amphiphilic block polymer and a click type covalent drug, and is used for regioselective delivery. By means of the click type covalent drug, covalent binding of azide-labeled tumor cells is achieved, normal cells which are not labeled by azide are not affected, and toxic and side effects on normal tissue are reduced. # imgabs0 #

The invention relates to an HER2 (human epidermal growth factor receptor 2) targeting antibody coupling gold (III) porphyrin medicine as well as a synthesis method and tumor treatment application thereof. The antibody coupling gold (III) porphyrin drug targeting HER2 is formed by connecting an anti-HER-2 trastuzumab and an A3B type gold (III) porphyrin complex through a linker, and the linker comprises a maleimide joint connected with an antibody and a self-elimination joint connected with the A3B type gold (III) porphyrin complex. The A3B type gold (III) porphyrin complex with anti-tumor activity is combined with trastuzumab with a specific recognition function as a carrier, the antibody is utilized to accurately strike tumor cells, a medicine is delivered to a tumor environment, the tumor targeting property of the gold (III) porphyrin complex is improved, and accurate treatment is realized. Distribution of drugs in the body can be improved, accumulation of the drugs in non-tumor sites can be reduced, the dosage of metal complexes is reduced, and toxic and side effects are reduced; the efficient delivery of gold drugs to tumor tissues can also be realized, and the cancer treatment effect is improved.

The present invention discloses an aromatic formyl-substituted tricyclic compound, a preparation method and a use thereof. Specifically, the aromatic formyl-substituted tricyclic compound of the present invention has a structure of formula (C), and as a BTK inhibitor, it has the advantages of high activity, good selectivity and low toxicity and side effects. #imgabs0#

The invention discloses skin antibacterial powder and a preparation method thereof, and relates to the technical field of skin antibacterial products. Comprising the following components in parts by weight: 1-3 parts of chlorhexidine acetate nanocrystals, 5-8 parts of radix sophorae flavescentis powder, 6-10 parts of cortex phellodendri powder, 3-6 parts of cortex dictamni powder, 2-4 parts of sail powder, 1-3 parts of tea polyphenol / chitosan nanoparticles, 15-25 parts of other Chinese herbal medicine extracts, 0.8-1.5 parts of borneol powder and 0.6-1 part of plant polysaccharide. The skin antibacterial powder is good in antibacterial activity, good in antibacterial durability, low in toxic and side effects and remarkable in wound repairing effect.

The invention relates to the technical field of biological medicine, in particular to a nano antibody conjugate as well as a preparation method and application thereof. The nano antibody conjugate comprises coupled antibody fusion protein and bortezomib; the antibody fusion protein is a fusion protein of elastin-like polypeptide and an anti-Her2 nano antibody. The nanometer antibody conjugate can improve the stability and enzyme selectivity of bortezomib and reduce the toxic and side effects of drugs, meanwhile, the tumor targeting effect is achieved by combining a tumor specific nanometer antibody targeting technology, and the nanometer antibody conjugate can be used for treating Her2 high-expression cancers and has excellent application and popularization value and potential.

The invention relates to the technical field of animal vaccine adjuvants, and discloses a composite biphasic adjuvant for a swine foot-and-mouth disease animal vaccine as well as a preparation method and application of the composite biphasic adjuvant, and the composite biphasic adjuvant comprises the following components in parts by weight: 50-65 parts of squalene; 0.1 to 0.5 part of phytosterol; 0.05 to 0.2 part of an antioxidant; 1 to 3 parts of chitosan oligosaccharide; 0.5 to 1 part of trehalose; 3-7 parts of an emulsifier; the deionized water is supplemented to 100 parts, and the antioxidant comprises 2-4 parts of a segmented copolymer PluronicF68; 0.5 to 1.5 parts of Tween 80; the antioxidant comprises the following components in parts by weight: 0.03 to 0.1 part of vitamin E (alpha-tocopherol); and 0.02 to 0.1 part of ascorbyl palmitate. By optimizing the squalene oil phase, the dual-antioxidant system and the synergistic emulsifier formula, the technical effects of high emulsion stability, high antigen delivery efficiency and remarkably enhanced immune response are achieved.

The invention relates to the field of biological medicine, in particular to a pyruvate-based respiratory system medicine synergist as well as a preparation method and application thereof. The synergist is a modified betulin derivative, and the preparation method comprises the following steps: adding betulin and triphenylphosphine into a solvent, uniformly stirring, and adding ammonia water for reaction to prepare aminated betulin; the preparation method comprises the following steps: adding (7-chloroimidazo [1, 2-A] pyridine-2-) methanol and phosphorus oxychloride into a solvent, carrying out heating reaction, and after the reaction is completed, carrying out post-treatment on a reaction solution to obtain an intermediate 1; adding aminated betulin, the intermediate 1 and magnesium sulfate into a solvent for reaction, and performing post-treatment on the reaction liquid after the reaction to obtain an intermediate 2; and adding 1-cyclopropyl-1, 3-dihydroimidazo [4, 5-C] pyridine-2-ketone, NaH and the intermediate 2 into a solvent, carrying out a stirring reaction, and carrying out post-treatment on the reaction liquid to obtain the 1, 3-dihydroimidazo [4, 5-C] pyridine-2-ketone. The modified betulin derivative disclosed by the invention is matched with pyruvate for use, so that the treatment effect of the pyruvate is remarkably enhanced.

The invention belongs to the technical field of drug co-delivery, and particularly relates to a nano-platform based on attenuated bacterial outer membrane vesicles and capable of achieving co-delivery of siRNA and adriamycin and a preparation method of the nano-platform. The preparation method comprises the following steps: synthesizing an ROS response type cationic polymer PTP; the preparation method comprises the following steps: preparing aptamer-DOX; preparing an ROS (reactive oxygen species) response type positive electric nano core PTP / 47aD; extracting and purifying the [delta] msbB OMVs; synthesizing a target functional unit DSPE-PEG2k-Angiopep-2 (Distearoyl Phosphate Polyethylene Glycol 2k-Angiopep-2); finally, the ROS response type co-delivery nano platform AO (at) PTP / 47aD is prepared and obtained. The co-delivery nano-platform prepared by the invention is relatively small in particle size, uniform in morphology and relatively high in biological safety, and has no obvious damage to various tissues and visceral organs. The glioblastoma immunopotentiator can be used as a general platform for gene delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and can comprehensively overcome immune resistance of glioblastoma.